🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Henan Institute of Cardiovascular Epidemiology clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Henan Institute of Cardiovascular Epidemiology as lead sponsor. Synced 26 Sep 2026
9Current trials
6Recruiting now
1Drug in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Henan Institute of Cardiovascular Epidemiology is the lead sponsor of 9 current clinical trials in our China register. 6 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Tirofiban. The most-studied condition is Coronary Artery Disease.

ClinicalTrials.gov trials by status

  • Recruiting667%
  • Not yet open111%
  • Active, closed111%
  • By invitation111%

Trials by phase

  • Not applicable556%
  • Observational333%
  • Phase 4111%
01

Clinical trials sponsored by Henan Institute of Cardiovascular Epidemiology

9 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Effects of Long-term Remote Ischemic Preconditioning on Clinical Outcome in Patients With Acute Myocardial Infarction
NCT07181356 · ClinicalTrials.gov ↗ · Acute Myocardial Infarction
Not applicable Recruiting 2025-01 China
Intracoronary rhTNK-tPA Versus Tirofiban in Patients With STEMI and High Thrombus Burden
NCT06769256 · ClinicalTrials.gov ↗ · ST-segment Elevation Myocardial Infarction (STEMI)
Drug: Tirofiban
Phase 4 Recruiting 2025-01 China
An Observational Study of Coronary Microvascular Disease of China
NCT06676137 · ClinicalTrials.gov ↗ · Coronary Microvascular Disease
Observational Recruiting 2024-11 China
CRIC Combined With MFT for Cardiovascular Adverse Events in Patients With Incomplete Revascularization of CAD
NCT06820970 · ClinicalTrials.gov ↗ · Coronary Artery Disease
Not applicable Recruiting 2025-08 China
Long-term of Remote Ischemic Preconditioning and Mindfulness in Patients With Mild Hypertension
NCT04753840 · ClinicalTrials.gov ↗ · Hypertension
Not applicable Recruiting 2021-07 China
Long-term Remote Ischemic Preconditioning Improves Myocardial Perfusion and Prognosis of Patients After CABG
NCT04779008 · ClinicalTrials.gov ↗ · Coronary Disease
Not applicable Recruiting 2021-03 China
Laparoscopic Adventitial Renal Denervation (RDN) for Refractory Hypertension
NCT07108829 · ClinicalTrials.gov ↗ · Refractory Hypertension or Drug-intolerant Hypertension
Not applicable Not yet open 2025-08 China
Influencing Factors and Outcomes of DCB Angioplasty
NCT06620458 · ClinicalTrials.gov ↗ · Coronary Artery Disease
Observational By invitation 2024-10 China
Prognostic Value of the AMR Measured After PPCI in STEMI Patients
NCT05653765 · ClinicalTrials.gov ↗ · Coronary Heart Disease, ST Elevation Myocardial Infarction
Observational Active, closed 2022-12 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Henan Institute of Cardiovascular Epidemiology trials

1 compound

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Henan Institute of Cardiovascular Epidemiology trials

9 conditions
Coronary Artery Disease2Acute Myocardial Infarction1ST-segment Elevation Myocardial Infarction (STEMI)1Refractory Hypertension or Drug-intolerant Hypertension1Coronary Microvascular Disease1Hypertension1Coronary Heart Disease1ST Elevation Myocardial Infarction1Coronary Disease1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China96

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Coronary Artery Disease

SponsorTrials
China National Center for Cardiovascular Diseases12
Nanjing First Hospital, Nanjing Medical University10
Second Affiliated Hospital, Zhejiang University, School of Medicine8
Shanghai Zhongshan Hospital7
Xijing Hospital6
Seung-Jung Park3
Second Hospital of Jilin University3
National University of Ireland, Galway, Ireland2
Philips Clinical & Medical Affairs Global2
Biosensors Europe2

Sponsors with the most current trials registered for this condition.

06

Questions about Henan Institute of Cardiovascular Epidemiology trials

How many clinical trials does Henan Institute of Cardiovascular Epidemiology sponsor?

Henan Institute of Cardiovascular Epidemiology is the lead sponsor of 9 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Henan Institute of Cardiovascular Epidemiology trials recruiting?

Yes. 6 of its 9 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Henan Institute of Cardiovascular Epidemiology testing?

Its current trials name 1 drug or biological as interventions. The most frequent are Tirofiban (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.